TITLE:
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

CONDITION:
Carcinoma, Non-Small-Cell Lung

INTERVENTION:
TLK286

SUMMARY:

      The purpose of this trial is to study the efficacy and safety of the triplet combination of
      TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced
      non-small cell lung cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Histologically confirmed non-small cell lung cancer (NSCLC)

          -  Stage IV or IIIB (disease that is not eligible for combined modality chemotherapy and
             radiation)

          -  Measurable disease by RECIST

          -  ECOG status of 0-1

          -  Adequate liver and renal function

          -  Adequate bone marrow reserves

        Exclusion Criteria:

          -  Prior chemotherapy, immunotherapy or biologic therapy for metastatic NSCLC

          -  Up to one prior adjuvant or neoadjuvant chemotherapy is allowed

          -  History of bone marrow transplantation or stem cell support

          -  Pregnant or lactating women
      
